🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

782 results for “S.A.” Clear

  1. Cemdisiran, Pozelimab

    Pharma Mar S.A.

    Paroxysmal nocturnal hemoglobinuria (PNH)

    phase 3 small molecule active

    1 trial

  2. Cidofovir, Brincidofovir

    Pharma Mar S.A.

    Adenovirus viremia

    phase 3 small molecule active

    1 trial

  3. Combipress 150 mg/5 mg επικαλυμμένα με λεπτό υμένιο δισκία, Combipress 150 mg/10 mg επικαλυμμένα με λεπτό υμένιο δισκία, Combipress 300 mg/10 mg επικαλυμμένα με λεπτό υμένιο δισκία, Combipress 300 mg/5 mg επικαλυμμένα με λεπτό υμένιο δισκία

    Pharma Mar S.A.

    Arterial Hypertension

    phase 3 small molecule active

    1 trial

  4. Conjunctival Provocation Test Grass-Mix LETI 30 HEP/ml, Conjunctival Provocation Test Olea europaea LETI 30 HEP/ml, Depigoid DUO Grass-Mix/Olea (1000 DPP/ml + 1000 DPP/ml), PLACEBO (Depigoid): the placebo is the solvent used in the investigational medicinal products’ (IMP) formulation. The resulting product is a suspension.

    Pharma Mar S.A.

    Allergic rhinoconjunctivitis with or without asthma due to clinically relevant sensitisation to grass and olive pollen.

    phase 3 small molecule active

    1 trial

  5. DCC-3014, DCC-3014, Placebo to match DCC-3014

    Pharma Mar S.A.

    Tenosynovial Giant Cell Tumor

    phase 3 small molecule active

    1 trial

  6. DEXAMETHASONE, Dexamethasonfosfaat Accord 4 mg/ml oplossing voor injectie/infusie, Kyprolis 10 mg powder for solution for infusion, Paracetamol 1000mg Tablets, Imnovid 2 mg hard capsules, Imnovid 1 mg hard capsules, DARZALEX 1800 mg solution for injection, LYNOZYFIC 200 mg concentrate for solution for infusion, Dermodrin 30 mg/2 ml soluție injectabilă, Imnovid 3 mg hard capsules, DEXAMETHASONE, Co-Trimoxazole 80/400mg Tablets, Kyprolis 30 mg powder for solution for infusion, LYNOZYFIC 5 mg concentrate for s

    Pharma Mar S.A.

    Relapsed Refractory Multiple Myeloma

    phase 3 small molecule active

    1 trial

  7. DOXORUBICIN, Pralatrexate, PREDNISONE, Belinostat, VINCRISTINE SULFATE, CYCLOPHOSPHAMIDE

    Pharma Mar S.A.

    Peripheral T-Cell Lymphoma

    phase 3 small molecule active

    1 trial

  8. DUOFAG, Chlorid sodný B. Braun 0,9 % infuzní roztok

    Pharma Mar S.A.

    Complicated skin wounds (wounds healing per secundam via granulation tissue) - either as a complication of healing of acute wounds (infected surgical or traumatic wounds) or chronic wounds, in both cases infected with S. aureus and/or P. aeruginosa.

    phase 3 small molecule active

    1 trial

  9. Depigoid Grass-Mix (1000 DPP/ml), Conjunctival Provocation Test Grass-Mix LETI 30 HEP/ml, The placebo to be used in the clinical trial is the solvent used in the investigational medicinal products’ (IMPs) formulation. The resulting product is a suspension., Depigoid FORTE Grass-Mix (3000 DPP/ml)

    Pharma Mar S.A.

    Allergic rhinoconjunctivitis with or without controlled asthma

    phase 3 small molecule active

    1 trial

  10. Dexa 8 mg inject JENAPHARM Injektionslösung, VELCADE 3.5 mg powder for solution for injection, Dexamethason 8 mg GALEN® Tabletten, Dexamethasone Tablets BP 2.0mg, Dexamethasone 2mg Tablets, Dexa-ratiopharm® 8 mg Injektionslösung, DARZALEX 20 mg/mL concentrate for solution for infusion, Dexamethason 8 mg JENAPHARM®

    GlaxoSmithKline Biologicals S.A.

    Multiple Myeloma

    phase 3 small molecule active

    1 trial

  11. Dexamethason 8 mg GALEN® Tabletten, Imnovid 1 mg hard capsules, Dexamethasone 2mg Tablets, Dexamethason 8 mg JENAPHARM®, Dexamethasone Tablets BP 2.0mg, Imnovid 4 mg hard capsules

    GlaxoSmithKline Biologicals S.A.

    Relapsed/Refractory Multiple Myeloma

    phase 3 small molecule active

    1 trial

  12. Dextrose / glucose 5% solution in water, Setrusumab

    Pharma Mar S.A.

    Osteogenesis imperfecta (OI)

    phase 3 small molecule active

    1 trial

  13. Dupixent 200 mg solution for injection in pre-filled syringe, Dupixent 300 mg solution for injection in pre-filled pen, Dupixent 300 mg solution for injection in pre-filled syringe, Dupixent 200 mg solution for injection in pre-filled pen

    Pharma Mar S.A.

    Atopic Dermatitis

    phase 3 small molecule active

    1 trial

  14. Endoxifen, Identical placebo tablets of Endoxifen manufactured by Intas Pharmaceuticals Limited, India. The placebo tablets were manufactured using the same excipients and the manufacturing process of endoxifen tablets. Like endoxifen 8 mg tablets, the placebo tablets are green coloured, round shape, biconvex, enteric coated tablets plain on both sides. The placebo for Endoxifen Tablets 8 mg was manufactured following the same procedure as the drug product without using endoxifen citrate.

    Pharma Mar S.A.

    Bipolar I Disorder

    phase 3 small molecule active

    1 trial

  15. Epidyolex 100 mg/ml oral solution

    Pharma Mar S.A.

    Dravet Syndrome, Tuberous sclerosis complex, Lennox-Gastaut Syndrome

    phase 3 small molecule active

    1 trial

  16. Erbitux 5 mg/mL solution for infusion, Ficlatuzumab, Ficlatuzumab, The corresponding placebo for this study is 0.9% Sodium Chloride injection for intravenous administration and this will be provided by the study site (and reimbursed by the Sponsor).

    Pharma Mar S.A.

    Head and Neck Squamous Cell Carcinoma (HNSCC)

    phase 3 small molecule active

    1 trial

  17. Etrasimod Arginine Blue

    Pharma Mar S.A.

    Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  18. Etrasimod Arginine Blue Placebo, Etrasimod Arginine Blue, Etrasimod Arginine Blue

    Pharma Mar S.A.

    Crohn's Disease

    phase 3 small molecule active

    1 trial

  19. Expanded access program for mepolizumab in subjects with hypereosinophilic syndrome.

    GlaxoSmithKline Biologicals S.A.

    Hypereosinophilic Syndrome

    phase 3 other active

    1 trial

  20. Eylea 40 mg/mL solution for injection in a vial

    Pharma Mar S.A.

    Retinopathy of prematurity (ROP)

    phase 3 small molecule active

    1 trial

  21. FAT EMULSIONS , Triheptanoin

    Pharma Mar S.A.

    Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)

    phase 3 small molecule active

    1 trial

  22. Fianlimab, LIBTAYO 350 mg concentrate for solution for infusion., Placebo for Fianlimab

    Pharma Mar S.A.

    Advanced Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  23. Fluticasone propionate,Salbutamol sulfate, ProAir® RespiClick®, ProAir® Digihaler®, Fluticasone propionate,Salbutamol sulfate

    Pharma Mar S.A.

    Asthma

    phase 3 small molecule active

    1 trial

  24. Fosmanogepix, POSACONAZOLE , AMPHOTERICIN B , CASPOFUNGIN , ISAVUCONAZOLE , MICAFUNGIN , TERBINAFINE , VORICONAZOLE , ANIDULAFUNGIN , -, Fosmanogepix

    Pharma Mar S.A.

    Invasive mold infections caused by Aspergillus spp., Fusarium spp., Lomentospora prolificans, Mucorales fungi, or other multidrug resistant molds

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources